Certara

MTPConnect funds Certara-Monash University program

Thursday, October 26, 2017

MTPConnect (the Medical Technologies and Pharmaceuticals Industry Growth Centre) will provide a proposed AUD750,000 provisional funding to the CertaraMonash University Industry Fellowship Program over two years, with proposed matched funding of AUD750,000 coming from Certara. Together, this funding will allow the Certara-Monash University Industry Fellowship Program to identify and develop the next generation of industry-experienced drug development scientists through training in clinical pharmacology, pharmacometrics and regulatory science to help shape the future and sustainability of the medical research sector in Australia. The program will be located at Monash University Faculty of Pharmacy and Pharmaceutical Sciences and will involve a combination of academic coursework, hands-on industry training, international industry/academic placements and research.

[Read More]

Certara launches Phoenix PK/PD modeling and simulation software Version 8.0

Tuesday, October 3, 2017

Certara, a global provider of model-informed drug development and regulatory science, announced the launch of Phoenix 8.0. Phoenix is the most advanced, intuitive, and widely-used software for pharmacokinetic (PK), pharmacodynamic (PD) and toxicokinetic (TK) modeling and simulation. Included in this Phoenix rollout are Phoenix WinNonlin 8.0, Phoenix NLME 8.0, Phoenix Validation Suite 8.0 and Phoenix in vitro-in vivo correlation (IVIVC) Toolkit 8.0.

[Read More]

Kyowa Hakko Kirin joins Certara’s Simcyp consortium

Wednesday, September 13, 2017

Certara, a provider of model-informed drug development and regulatory science, announced that Kyowa Hakko Kirin has joined the Simcyp Consortium and licensed the Simcyp Population-based Simulator. Kyowa Hakko Kirin is the 36th leading biopharmaceutical company and the 11th Japanese pharmaceutical company to join the Consortium. Member companies meet in a pre-competitive environment and work together to progress the evolution of modeling and simulation (M&S) and the Simcyp Simulator.

[Read More]

Certara adds externalization technology to its D360 scientific informatics platform

Thursday, August 10, 2017

Certara, a global provider of model-informed drug development and regulatory science, has added externalization technology to its D360 scientific informatics platform. The resulting new product, D360 Partner, facilitates collaboration between sponsors and their external research partners. Those external collaborators could include academic institutions, contract research organizations or third-party research groups. Those partners all have similar data access and communication requirements to members of an internal research project.

[Read More]

EQT VII acquires Certara for $850M

Wednesday, July 12, 2017

The EQT VII fund has agreed to acquire Certara, a provider of technology-driven decision support solutions for drug development, for an enterprise value of $850 million. The company is being acquired from Arsenal Capital Partners. As part of the transaction, Arsenal Capital Partners will retain a minority ownership stake in Certara, with the Company’s current management team, led by Edmundo Muniz, M.D., Ph.D., continuing to lead the organization, building on a multi-year track record of both organic growth and strategic acquisitions.

[Read More]

Certara launches CODEx

Tuesday, June 6, 2017

Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, launched its Clinical Outcomes Database Explorer (CODEx). An intuitive, web-based platform, CODEx enables drug development teams to easily visualize, explore, analyze and communicate content from Certara’s Clinical Trial Outcomes Databases and assess a given compound’s probability of success against competitor drugs.

[Read More]